Video Experimental Relacionado
Updated: Jan 8, 2026
Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets
Published on: February 2, 2024
ADN tumoral circulante como herramienta pronóstica para el adenocarcinoma ductal pancreático tratado quirúrgicamente
Trine Aaquist1, Tenna Vesterman Henriksen2, Lea Lecanda Mariager Jakobsen3
1Department of Pathology, Odense University Hospital, Odense, Denmark; Odense Pancreas Center (OPAC), Odense University Hospital, Odense, Denmark; Department of Clinical Research, Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark; OPEN - Open Patient data Explorative Network, Odense University Hospital, Region of Southern Denmark.
Introduction:
Pancreatic ductal adenocarcinoma (PDAC) has a high risk of early recurrence after surgery. We evaluated the utility of circulating tumour DNA (ctDNA) taken at different time points as a prognostic tool. Secondary aims were prognostic value of ctDNA combined with plasma carbohydrate antigen (CA)-19-9 and of peritoneal tumour DNA (ptDNA).
Methods:
A total of 75 patients were included. Plasma samples were obtained preoperatively, 1 month, and 7-9 months after resection. Peritoneal lavage fluid (PLF) was collected preoperatively and 7-9 months after resection. Cell-free DNA (cfDNA) from plasma and ptDNA was analysed using mutation specific digital droplet PCR assays in a tumour-informed apprach. Kaplan-Meier survival curves, univariable, and multivariable Cox proportional hazard models were used to assess overall survival (OS) and recurrence-free survival (RFS).
Results:
Preoperatively, detectable ctDNA was an independent risk factor for OS (HR=1.88, p=0.047). Detectable ctDNA 7-9 months after surgerywas an independent risk factor for RFS (HR=4.48, p=0.017). Detectable ctDNA 1 month after surgery showed decreased RFS (HR=1.98, p=0.055). Preoperative, 1-month, and 7-9 months postoperative positivity for ctDNA and/or CA 19-9 showed a significantly worse median OS (p=0.024, p=0.008, and p=0.0003). We did not find association of ptDNA with OS or RFS, but ptDNA detection 7-9 months after surgery was associated with peritoneal RFS (p=0.003).
Conclusion:
Our data indicate that detectable ctDNA in plasma taken before and 7-9 months after surgery holds independent prognostic value in surgically treated PDAC. Combination of ctDNA with CA-19-9 may be a particularly strong prognosticator, which should be confirmed in future studies.
